

STATEMENT OF SUPPORT

FOR THE USE OF EUROPEAN PHARMACOGENOMIC GUIDELINES

The Horizon 2020 subsidized Ubiquitous Pharmacogenomics (U-PGx) project aims to improve the safety and efficacy of pharmacotherapy for every European citizen by enabling the use of clinical pharmacogenomics (PGx). Every patient is different, and so is their response to certain drugs. While a certain medication might show good efficacy in one person without causing any adverse drug events, another patient might experience insufficient efficacy or adverse reactions when taking the same drug. These differences in drug response are partly attributable to individual genetic differences, so-called 'pharmacogenomic (PGx) variants'. Testing patients for these PGx variants allows healthcare providers to provide their patients with a more personalized drug therapy, ultimately helping to increase the efficacy and safety of medical treatments.

We believe European guidelines for pharmacogenomics will enable more healthcare institutions to use pharmacogenomic information in their clinical decisions. The creation of these guidelines was initiated in 2005 by the Dutch Pharmacogenetics Working Group (DPWG) of The Royal Dutch Pharmacists Association to be integrated in clinical decision support systems in the Netherlands (Swen et al 2008, Swen et al 2011). These guidelines have been updated, translated, adapted and expanded for European use in the U-PGx project. These translated guidelines will be made publicly available.

As healthcare professionals, we aim to provide the best possible care for our patients. To this end we strive to include relevant determinators that explain the interindividual variability in clinical decision making. The efforts in U-PGx to create European guidelines, address implementation barriers and determine the clinical value is a great example of innovative patient care. The PGx guidelines are valuable to determine if pharmacogenomic variants are relevant for a certain drug.

It is in this context that the healthcare professional and patient organisations listed below welcome publically available pharmacogenomic guidelines and their use across Europe.

By our explicit inclusion in this statement of support, we agreed on the following:

- We believe PGx can help us understand patients response to certain drugs or even predict their response beforehand;
- We believe publically available, evidence-based PGx guidelines are valuable to European citizens;
- We support the implementation of PGx as a therapeutic tool to help optimize pharmacotherapy;
- We encourage the use of the guidelines from the U-PGx project in healthcare settings across Europe;
- We encourage the dissemination of best practices and case reports on the use of PGx in international peer-reviewed journals;
- We believe the PGx guidelines should continue to be frequently updated, translated and distributed when the U-PGx project has ended.



HEALTHCARE ORGANISATIONS**CONTACTS****DATE OF ENDORSEMENT****Prof. Ylva Böttiger**

28/11/2017

Chairman of the Executive Committee
of the EACPT**Joan Peppard**

7/11/2017

President EAHP

**Dr. Cor Oosterwijk**

3/2/2018

Secretary-General EGAN

**Dorothea Dalig**

9/3/2018

Vice President of European Affairs

**Darragh J O'Loughlin**

26/3/2018

Secretary General

**Dr. Cor Oosterwijk**

3/2/2018

Managing Director VSOP



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 668353.